On June 12, 2018 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, reported data from 17 patients enrolled in the Phase Ia portion of its ongoing Phase I Safety Trial at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting Poster Session, held in Chicago June 1-5, 2018 (Press release, Bexion, JUN 12, 2018, View Source [SID1234527440]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the poster presentation entitled, "First-in-class Phase Ia Study of BXQ-350 for Solid Tumors and Gliomas", the preliminary data showed:
9 patients with Glioblastoma Multiforme (GBM); 8 patients with other solid tumors
Patients had a median 7 prior systemic therapies
No Dose Limiting Toxicities (DLTs)
No treatment –related serious adverse events (SAEs)
Most common treatment-related moderate AEs were transient fatigue
Best response in 7 patients completing to day 113:
1 Partial Response (appendiceal carcinoma)
6 Stable Disease (improved day 113 RANO/RECIST
1 High Grade Glioma Stable Disease >19+ months
"Bexion’s team was excited to share our Phase Ia data at the ASCO (Free ASCO Whitepaper) conference," stated Dr. Ray Takigiku, Founder and CEO. "With this promising data indicating the potential for a tumor agnostic approach, Bexion is now enrolling patients with solid tumors and gliomas in Phase 1b, and we are initiating efforts to towards a Phase 1 trial in pediatrics and combination Phase 2 studies in adults".
About BXQ-350
BXQ-350 is a unique formulation of a synthetically produced, human lysosomal protein, Saposin C (sphingolipid activator protein, or SapC), and the phospholipid dioleoylphosphatidylserine (DOPS).